Weill Cornell Medical Center

Running trials

• Not yet recruiting

  Cilostazol for Prevention of Recurrent Stroke Trial

  NCT07174414· Phase 3· Stanford University· Source

• Recruiting

  A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

  NCT07214376· Pulnovo Medical, Inc.· Source

• Recruiting

  ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

  NCT07559903· Emory University· Source

• Recruiting

  Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  NCT07061951· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

  NCT07249528· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

  NCT07548164· Phase 3· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

  NCT05723926· Javelin Medical· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

  NCT07217067· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  NCT06661915· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  NCT06439836· Phase 1· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

  NCT06814145· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

  NCT06503614· Phase 2· John Sfakianos· Source

• Active, not recruiting

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· Phase 3· Genmab· Source

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

  NCT06611553· National Cancer Institute (NCI)· Source

• Recruiting

  Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

  NCT06377371· Phase 4· Weill Medical College of Cornell University· Source

• Recruiting

  Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

  NCT06549465· Phase 2· Convergent Therapeutics· Source

• Active, not recruiting

  Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

  NCT06169215· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

  NCT06455098· Biosense Webster, Inc.· Source

• Recruiting

  Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

  NCT06263426· Johns Hopkins University· Source

• Enrolling by invitation

  Pivotal Trial of the Boomerang Catheter for pDVA

  NCT06311773· Aveera Medical, Inc.· Source

• Recruiting

  Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

  NCT06305728· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT05976763· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Recruiting

  A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

  NCT06083922· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Cryoablation for Monomorphic Ventricular Tachycardia

  NCT05675865· Adagio Medical· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

  NCT05724108· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  NCT05602194· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Registry for People With T-cell Lymphoma

  NCT05978141· Memorial Sloan Kettering Cancer Center· Source

• Active, not recruiting

  Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  NCT05600894· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

  NCT05893498· CathWorks Ltd.· Source

• Recruiting

  Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  NCT05633615· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

  NCT05726864· Phase 1/2· Elicio Therapeutics· Source

• Active, not recruiting

  Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

  NCT05669482· Phase 1/2· Verastem, Inc.· Source

• Recruiting

  A Digital Intervention for Post-Stroke Depression and Executive Dysfunction

  NCT05507138· Phase 2· Weill Medical College of Cornell University· Source

• Recruiting

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

Showing 50 of 165.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Acute lymphoblastic leukaemia6 recruiting
• Prostate cancer6 recruiting
• Bladder cancer5 recruiting
• Stroke4 recruiting
• Acute myeloid leukaemia3 recruiting
• Atrial fibrillation3 recruiting
• Kidney cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Ovarian cancer3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Coronary artery disease2 recruiting
• Follicular lymphoma2 recruiting
• High blood pressure2 recruiting
• Meningioma2 recruiting
• Multiple myeloma2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Down syndrome1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Analysis of Biologic Signatures in Crohn's Patients Undergoing Surgery

  NCT06146335· Weill Medical College of Cornell University· Source

• Completed

  A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

  NCT06292923· Phase 2· Tiziana Life Sciences LTD· Source

• Recruiting

  IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  NCT06119685· Phase 1/2· Indapta Therapeutics, INC.· Source

• Completed

  Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

  NCT05673811· Phase 2· Theriva Biologics SL· Source

• Terminated

  Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

  NCT04936230· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

  NCT05427812· Phase 1/2· Ichnos Sciences SA· Source

• Terminated

  Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

  NCT05224661· Center for International Blood and Marrow Transplant Research· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source

• Completed

  BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease

  NCT04930666· Columbia University· Source

• Completed

  Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

  NCT04600336· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Terminated

  A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04776018· Phase 1/2· Takeda· Source

• Completed

  INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

  NCT04455841· Phase 1/2· Incyte Corporation· Source

• Completed

  The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

  NCT05524844· Columbia University· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Recruiting

  A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

  NCT04462770· Phase 3· Epygenix· Source

• Completed

  Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  NCT04396860· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  NCT04256317· Phase 2/3· Taiho Oncology, Inc.· Source

• Completed

  Determination of the Optimal Treatment Target in Ulcerative Colitis

  NCT04259138· Phase 4· Alimentiv Inc.· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

  NCT03689699· Phase 1/2· Mark Stein· Source

• Completed

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

  NCT03031730· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source

• Completed

  Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687· Phase 3· NRG Oncology· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

  NCT03011372· Phase 2· Incyte Corporation· Source

• Completed

  Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT02844816· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT02744612· Phase 2· City of Hope Medical Center· Source

• Completed

  AASUR in High Risk Prostate Cancer

  NCT02772588· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Completed

  Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

  NCT02269280· Phase 2· M.D. Anderson Cancer Center· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

  NCT01908777· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Completed

  Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  NCT01793233· Children's Oncology Group· Source

• Completed

  Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

  NCT01742299· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

  NCT01757665· Edwards Lifesciences· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

  NCT01286272· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

  NCT01149083· Phase 2· National Cancer Institute (NCI)· Source

Showing 50 of 58.

Conditions

Diseases this institution publishes on or runs trials for.

• Immune thrombocytopenia (ITP)4 works · 0 trials